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In the past decades, the prognosis of patients with idio-pathic dilated cardiomyopathy (IDCM) has improved 
after the advances in medical therapy and the introduction 
of device therapy, namely, cardiac resynchronization therapy 
and implantable cardioverter-defibrillator.1–6 Nonetheless, 
10-year survival remains <60%, with deaths often preceded 
by numerous heart failure exacerbations.5,6 This reflects, at 
least in part, the difficulty in assessing the individual risk in 
patients with IDCM in whom clinical course varies widely, 
ranging from progressive heart failure and sudden cardiac 
death to left ventricular (LV) reverse remodeling (RR). 
The latter is characterized by a decrease in LV volumes, 
combined with a substantial improvement in systolic func-
tion. Studies in general heart failure populations and IDCM 
patients reported that approximately one third of patients 
treated with optimal medical therapy (OMT) experienced 
LV-RR at midterm follow-up, and this was associated with 
favorable long-term prognosis.7–9 However, in clinical prac-
tice, the prediction of LV-RR after the optimization of medi-
cal therapy still remains particularly difficult. Two recent 
studies reported that late gadolinium enhancement (LGE) 
detected by cardiovascular magnetic resonance (CMR) may 
be a useful marker for predicting LV-RR in patients with non-
ischemic cardiomyopathy.10,11 However, these studies had a 
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short-term follow-up (5 and 12 months, respectively), and the 
recovery of LV function was likely prompted by the resolu-
tion of transient myocardial damage in a sizeable number of 
patients. Accordingly, it remains uncertain whether LGE is 
a predictor of LV-RR in patients with IDCM in response to 
OMT. In addition, at the moment, there are no data on the 
potential interplay between the changes in LGE over time and 
LV remodeling. Based on these premises, we conducted the 
current study with the following aims: (1) to assess whether 
LGE may be used to predict LV-RR at 2-year follow-up in 
patients with IDCM after optimization of medical therapy, 
and (2) to investigate the interaction between LGE variation 
and LV remodeling  during follow-up.
Methods
Study Population
Between May 2009 and July 2010, 112 consecutive patients with 
IDCM diagnosed in the preceding 12 months were prospectively 
evaluated at our institution (a tertiary referral hospital) for study 
enrollment. The diagnosis of IDCM was made according to World 
Health Organization criteria12 and the evidence of an increased LV 
end-diastolic diameter indexed to body surface area at transthorac-
ic echocardiography and a reduced LV ejection fraction based on 
published reference ranges.13 Invasive coronary angiography was 
performed in all patients to exclude significant coronary artery ste-
nosis.14 Exclusion criteria included active myocarditis, peripartum 
cardiomyopathy, extracardiac systemic features of sarcoidosis, che-
motherapy-induced cardiomyopathy, drug abuse or excessive alcohol 
consumption, tachycardia-induced cardiomyopathy, severe valvular 
disease, untreated hypertension, hypertrophic cardiomyopathy, car-
diac amyloidosis, thyroid dysfunction, estimated glomerular filtration 
rate <30 mL/min, and contraindications to CMR. Active myocarditis 
was excluded by the absence of classical clinical feature and the in-
crease in troponin I at study entry.
Study Protocol
The study protocol consisted of the following baseline investiga-
tions: complete clinical evaluation, 12-lead ECG, echocardiog-
raphy, and blood sampling, including amino-terminal probrain 
natiuretic peptide dosage and contrast-enhanced CMR. All the in-
vestigations were performed within 1 week from the study enroll-
ment. Patients were treated with angiotensin-converting enzyme 
(or angiotensin II receptor inhibitors) and β-blockers, in addition to 
diuretics, when clinically indicated. Neurohormonal medications 
were titrated to maximally tolerated dose (within 3–6 months), 
which was defined as OMT. Medications at study entry and OMT 
are reported in Table 1. Patients underwent clinical follow-up at 
our outpatient clinic every 3 to 6 months up to July 2012. CMR 
was repeated at 24-month follow-up. The protocol was approved 
by our institution’s ethical committee, and all patients gave written 
informed consent.
Transthoracic Echocardiography
Transthoracic echocardiography was performed in all patients and 
consisted of M-mode, 2-dimensional, and Doppler imaging. For 
LV diastolic function, from the apical 4-chamber view transmitral 
flow pattern was assessed by pulsed-wave Doppler echocardiogra-
phy. Early (E) and late (A) diastolic filling velocities, E/A ratio, and 
E deceleration time were measured. For patients with atrial fibrilla-
tion, only E wave was considered. All studies were interpreted by an 
experienced operator (V.S.) blinded to clinical and CMR data. Left 
ventricular diastolic function was graded as (1) normal, (2) impaired 
relaxation, (3) pseudonormal, and (4) restrictive filling. Changes 
in the mitral flow pattern during Valsalva maneuver, pulsed-wave 
Doppler of pulmonary vein flow, or mitral annular velocities sampled 
by tissue Doppler imaging were used to differentiate a pseudonormal 
from a normal transmitral flow pattern.15 LV diastolic dysfunction 
was defined by the presence of restrictive filling pattern. Mitral regur-
gitation was graded semiquantitatively as mild, moderate, or severe 
according to current recommendations.16
CMR Protocol
All patients were examined with 1.5-T unit (CVi; GE-Healthcare, 
Milwaukee, WI) at study enrollment and follow-up using the same 
protocol. Studies were performed using dedicated cardiac software, 
a phased-array surface receiver coil, and vectocardiogram trigger-
ing. Cine images in horizontal, vertical, and short-axis views were 
acquired using breath-hold cine steady-state free precession se-
quence. For the quantification of biventricular volumes, stroke vol-
ume, ejection fraction, and LV mass cine images were acquired in 
a stack of contiguous short-axis slices from base to apex. Sequence 
parameters were as follows: field of view, 350 to 400 mm; slice 
thickness, 8 mm; repetition time/echo time, 3.2/1.6 ms; flip angle, 
60°; matrix, 224×192; phases, 30; no interslice gap. Ten to 20 min-
utes after intravenous administration of 0.2 mmol/kg gadolinium–
DTPA, LGE images were acquired using segmented T1-weighted 
gradient-echo inversion-recovery sequence in the same views used 
for cine images. The inversion time was individually adapted to sup-
press the signal of normal myocardium (220–300 ms). Sequence 
parameters were as follows: field of view, 380 mm; slice thickness, 
8 mm; repetition/echo time, 4.6/1.3 ms; flip angle, 20°; matrix, 
256×192; no interslice gap.
Image Analysis
All CMR studies were analyzed off-line using a workstation 
(Advantage; GE-Healthcare, Milwaukee, WI) with a dedicated soft-
ware (MASS 6.1; Medis, Leiden, The Netherlands). The analysis 
was started with postcontrast images. Presence of LGE was as-
signed by the consensus of 2 experienced operators (P.G.M. and 
A.B.) blinded to clinical data. A third blinded operator (M.L.) ad-
judicated LGE in case of disagreement (n=2). When present, LGE 
was automatically quantified on short-axis images by 1 operator 
(P.G.M.). For each short-axis slice, after tracing the endocardial 
and epicardial borders, a region of interest averaging 50 mm2 was 
defined within normal myocardium with homogeneously nulled 
signal and without artifacts. Myocardial LGE was defined as ar-
eas with signal intensity >6 SD above the mean signal intensity 
of normal myocardium and expressed as percentage of LV mass.17 
LV and right ventricular (RV) volumes, stroke volume, mass, and 
ejection fraction were quantified using the stack of cine short-axis 
images. At least 2-week apart, in 15 anonymized and randomly cho-
sen LGE-positive patients, LGE extent was quantified twice by the 
same operator (P.G.M.) to assess intraobserver variability. LV-RR 
was defined as an increase in LV ejection fraction ≥10 U, combined 
with a decrease in LV end-diastolic volume ≥10% at follow-up.7
Statistical Analysis
Continuous variables were expressed as mean±SD or median and 
25th to 75th percentiles and categorical variables as frequency 
with percentage. For continuous variables, Δ expressed the differ-
ence between follow-up and baseline values. LGE expansion was 
defined as ΔLGE extent >75th percentile. Student independent 
t tests or Mann−Whitney tests were used as appropriate to com-
pare continuous variables between patients with and without  LV-RR. 
Comparisons between categorical variables was performed us-
ing the χ2 or Fisher exact test, if the expected cell count was <5. 
Student dependent t test and Wilcoxon sign-rank test were used as 
appropriate to compare continuous variables at baseline and follow-
up. Correlations between continuous variables were examined as 
appropriate by Pearson or Spearman ρ correlation coefficients. 
Univariate logistic regression analysis was used to study the asso-
ciation of baseline variables with LV-RR. Interactions between LGE 
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Table 1. Baseline Characteristics of the Whole Study Population and Patients With and Without LV-RR
Variables All (n=58) LV-RR (n=22) No LV-RR (n=36) P Value
Age, y 55±12 58±14 52±13 0.167
Female, n (%) 39 (67) 10 (45) 9 (25) 0.151
BMI, kg/m2 26±4 26±4 26±3 0.483
Heart rate, bpm 66±12 74±13 62±8 <0.001
Systolic BP, mm Hg 116±15 114±15 119±17 0.333
Diastolic BP, mm Hg 71±11 70±10 74±11 0.275
Previous HF hospitalization, n (%) 15 (26) 7 (32) 8 (29) 0.715
Duration of CM, mo 5±2 4±3 6±2 0.282
Family history of CM 15 (30) 6 (27) 13 (36) 0.572
Hypertension, n (%) 24 (41) 9 (41) 15 (42) 0.955
Diabetes mellitus, n (%) 7 (12) 2 (9) 5 (14) 0.698
Smoking, n (%) 23 (40) 9 (41) 14 (39) 0.897
NYHA class I/II/III/IV 33/20/5/0 6/11/5/0 27/9/0/0 <0.001
NYHA class >I 25 (43) 16 (73) 9 (25) <0.001
NT-proBNP, ng/L 668 (222–1739) 1292 (481–1866) 433 (118–1038) 0.038
eGFR, mL/min 92±31 83±32 97±29 0.158
Serum sodium, mEq/L 138±2 138±2 139±2 0.895
Atrial fibrillation, n (%) 2 (3) 1 (4) 1 (3) 0.938
LBBB, n (%) 14 (23) 7 (32) 7 (21) 0.529
QRS duration, ms 120±25 125±30 116±20 0.317
Diastolic dysfunction 8 (14) 4 (18) 4 (11) 0.462
Moderate/severe MR 16 (28) 7 (32) 9 (25) 0.694
LGE, n (%) 26 (45) 3 (14) 23 (64) <0.001
LGE extent, % of LV 5.94 (3.33–10.21) 5.97 (3.26–10.53) 5.45 (3.38–8.50) 0.821
LV-EDVi, mL/m2 125±28 134±34 113±14 <0.001
LV-ESVi, mL/m2 81±31 106±34 65±15 <0.001
LV-Mi, g/m2 90±20 97±21 86±19 0.044
LV-SVi, mL/m2 46±12 40±14 49±10 0.006
LV-EF, % 37±10 28±10 43±8 <0.001
LV-EF <35%, n (%) 22 (38) 16 (73) 6 (17) <0.001
RV-EDVi, mL/m2 76±17 78±22 75±13 0.640
RV-ESVi, mL/m2 32±15 39±20 28±9 0.008
RV-SVi, mL/m2 44±10 39±10 47±9 0.002
RV-EF, % 59±11 52±13 63±8 <0.001
ACEi/ARBs, n (%) 29 (50) 12 (54) 17 (47) 0.447
Dosage* 0.30±0.17 0.25±0.00 0.33±0.21 0.623
β-blockers, n (%) 32 (55) 10 (45) 22 (61) 0.146
Dosage* 0.26±0.26 0.18±0.09 0.32±0.32 0.191
Spironolactone, n (%) 8 (14) 4 (18) 4 (11) 0.336
Furosemide, n (%) 26 (45) 10 (45) 16 (41) 0.742
ACEi/ARBs, n (%) 53 (91) 19 (86) 34 (94) 0.287
Dosage* 0.70±0.29 0.70±0.30 0.70±0.28 0.988
β-blockers, n (%) 49 (84) 19 (86) 30 (83) 0.757
Dosage* 0.57±0.25 0.60±0.26 0.55±0.24 0.614
Spironolactone, n (%) 20 (34) 9 (41) 11 (31) 0.421
Furosemide, n (%) 21 (36) 6 (27) 15 (42) 0.268
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II inhibitor; BMI, body mass index; BP, blood pressure; CM, cardiomyopathy; 
EDVi, end-diastolic volume index; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ESVi, end-systolic volume index; HF, heart failure; 
LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricular; Mi, mass index; MR, mitral regurgitation; NT-pro-BNP, amino-
terminal probrain natiuretic peptide; NYHA, New York Heart Association; RR, reverse remodeling; RV, right ventricular; and SVi, stroke volume index.
*Dosage expressed the ratio between the daily dose and the maximum recommended dose of medication. 
 by guest on January 20, 2016http://circimaging.ahajournals.org/Downloaded from 
Masci et al  Myocardial Fibrosis and LV Remodeling  793
and other baseline variables were evaluated (P<0.10 was considered 
statistically significant for interaction). Multivariate logistic regres-
sion analysis with stepwise selection procedure (P<0.05 for entry; 
P>0.10 for removal) was used to assess the influence of covariates 
on LV-RR. Variables with P<0.10 at univariate analysis were in-
troduced in the multivariate model as covariates. Considering the 
correlation between LV ejection fraction and LV end-systolic vol-
ume (r=−0.875; P<0.001) and the importance of the latter on LV 
remodeling, LV end-systolic volume (model 1) and LV ejection 
fraction (model 2) were introduced separately in the multivariate 
analysis. Because RV ejection fraction and end-systolic volume 
were strongly related (r=−0.827, P<0.001), only RV ejection frac-
tion was introduced in the 2 models. For each model, the incremen-
tal value in predicting LV-RR by the stepwise inclusion of CMR 
functional parameters (RV ejection fraction, LV volumes, and ejec-
tion fraction) and LGE, in addition to clinical parameters (age, heart 
rate, and New York Heart Association class >I), was assessed by 
the χ2 test using omnibus test of model coefficients. In addition, we 
also performed Bayesian model averaging to address model uncer-
tainty, producing a posterior probability for each possible model 
and predictor, implemented with R package (R project for statistical 
computing).18 Intraclass correlation coefficient and Bland–Altman 
analysis (MedCalc, Belgium) were used to assess intraobserver 
variability for LGE extent.19 All tests were 2-tailed, and P<0.05 was 
considered statistically significant. With the exception of Bland–
Altman and Bayesian model averaging, analyses were performed 
using SSPS version 15 (SPSS, Chicago, IL).
Results
Study Population
Of the 81 patients initially enrolled in the study, 8 patients 
died (6 for cardiac causes), 4 declined to repeat CMR, and 
11 underwent device implantation during the study period. 
The final study cohort was made up of 58 patients, and all 
patients had an increased LV end-diastolic volume indexed to 
body surface area and reduced LV ejection fraction at baseline 
CMR compared with published reference ranges normalized 
for age and sex20 (Figure 1). Twenty-two patients (38%) expe-
rienced LV-RR at follow-up. Baseline characteristics of the 
overall study population and patients with and without LV-RR 
are reported in Table 1. At baseline, patients with LV-RR had 
higher heart rate, were more symptomatic, and showed higher 
amino-terminal probrain natiuretic peptide levels than patients 
Figure 1. Study protocol. CMR indicates cardio-
vascular magnetic resonance; and IDCM, idiopathic 
dilated cardiomyopathy.
Table 2. Changes in CMR Parameters During Follow-Up in Patients With and Without LGE at Baseline
Variables
Patients Without LGE Patients With LGE
Baseline/Follow-Up Δ Value P Value Baseline/Follow-Up Δ Value P Value
LV-EDVi, mL/m2 134±32/98±17 −36±6 <0.001 115±16/116±26 +1±4 0.828
LV-ESVi, mL/m2 89±37/47±12 −42±7 <0.001 70±14/75±29 +5±5 0.385
LV-Mi, g/m2 91±19/76±20 −14±4 0.001 90±22/87±20 −3±3 0.408
LV-SVi, mL/m2 45±14/51±8 +6±2 0.021 46±11/44±9 −2±2 0.316
LV-EF, % 35±13/52±7 +17±3 <0.001 40±10/39±11 −1±2 0.646
RV-EDVi, mL/m2 79±19/77±15 −2±2 0.320 72±13/72±17 +0±2 0.866
RV-ESVi, mL/m2 35±18/27±11 −9±3 0.004 29±8/31±14 +2±2 0.320
RV-SVi, mL/m2 44±11/51±9 +7±2 0.002 43±10/43±10 0±2 0.961
RV-EF, % 57±13/66±8 +9±2 0.001 60±9/60±10 0±2 0.932
Data are expressed as mean±SD. Δ value is the difference between follow-up and baseline values and is expressed as 
mean±SE. CMR indicates cardiovascular magnetic resonance; EDVi, end-diastolic volume index; EF, ejection fraction; ESVi, end-
systolic volume index; LGE, late gadolinium enhancement; LV, left ventricular; Mi, mass index; RV, right ventricular; and SVi, stroke 
volume index.
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without LV-RR. Myocardial LGE was observed less com-
monly in patients with LV-RR than in those without LV-RR. 
Patients with LV-RR had larger LV volumes and mass but 
lower stroke volume and ejection fraction than those without 
LV-RR. In addition, RV end-systolic volume was higher, but 
stroke volume and ejection fraction were lower in patients 
with LV-RR.
Relationship Between LGE at Baseline and LV-RR
All patients with LGE at baseline (n=26; 45%) showed LGE 
at follow-up with the same pattern (midwall [n=18]; patchy 
[n=7]; subendocardial [n=1]), and none of the patients with-
out LGE at baseline developed LGE at follow-up. Changes 
in CMR parameters during follow-up are shown in Table 2. 
Patients without LGE at baseline showed significant reduction 
in LV volumes and mass with a concurrent increase in stroke 
volume and ejection fraction (Figure 2). In this group, a consis-
tent reduction in RV end-systolic volume was observed, lead-
ing to an improvement in stroke volume and ejection fraction. 
Conversely, patients with LGE at baseline experienced neither 
a decrease in LV and RV volumes nor an improvement in stroke 
volume and ejection fraction (Figure 3). As a result, 3 (11%) 
and 19 (59%) patients with and without LGE at baseline CMR 
experienced LV-RR at follow-up (P<0.001). During follow-up, 
normalization of LV volumes, mass, and function20 occurred 
only in 6 patients, none of which had LGE at baseline.
LGE Variation During Follow-Up and  
LV Remodeling
The extent of LGE increased significantly during follow-up 
(from 5.94% [3.33%–10.21%] to 6.76% [3.79%–10.80%]; 
P=0.034). The median value of ΔLGE extent was 0.95% 
(0.00%–3.42%). There was an inverse relationship between 
ΔLV ejection fraction and ΔLGE extent (Spearman ρ, −0.440; 
P=0.041). Five patients (9%) showed LGE expansion during 
follow-up (ΔLGE extent >3.42%), and among these none 
experienced LV-RR and 4 had a decrease in LV ejection frac-
tion ≥10 U at follow-up (Table 3; Figure 4).
Figure 2. A 52-year-old woman with 
8-month history of idiopathic dilated car-
diomyopathy, left bundle branch block, 
and dyspnea on exertion (New York Heart 
Association class II). Baseline postcon-
trast cardiovascular magnetic resonance 
images in horizontal (A) and vertical long 
axis (B) and midventricular short axis (C) 
did not show late gadolinium enhance-
ment. End-diastolic (D and F) and end-
systolic (E and G) horizontal long-axis 
images at baseline (D and E; Movie I 
in the online-only Data Supplement) 
and follow-up (F and G; Movie II in the 
online-only Data Supplement) showing a 
reduction in left ventricular (LV) volumes 
(end-diastolic volume from 208 to 112 
mL/m2; end-systolic volume from 169 to 
61 mL/m2) and improvement in function 
(LV ejection fraction from 18% to 46%).
Figure 3. A 51-year-old man with 11-month history of idiopathic dilated cardiomyopathy complaining of episodes of palpitation and 
asthenia. Baseline postcontrast basal (A) and midventricular (B) short-axis images showed late gadolinium enhancement (LGE) of the 
septum and left ventricular (LV) inferolateral wall (arrows). At follow-up, postcontrast basal (C) and midventricular (D) short-axis images 
showed an increase in LGE extent (from 4.43% to 7.52%; Δ value, 3.09%). End-diastolic (E and G) and end-systolic (F and H) horizontal 
long-axis images at baseline (E and F; Movie III in the online-only Data Supplement) and follow-up (G and H; Movie IV in the online-only 
Data Supplement) showed no significant changes in LV volumes (end-diastolic volume from 108 to 107 mL/m2; end-systolic volume from 
55 to 54 mL/m2) and function (ejection fraction 49% at baseline and follow-up).
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Reproducibility of LGE Extent
Intraobserver variability for LGE extent was low, show-
ing a mean bias of 0.92% (95% confidence intervals, 1.97% 
to −1.3%; limits of agreement, 4.62% to −2.78%). The intra-
class correlation coefficient between the repeated measure-
ments was high (intraclass correlation coefficient, 0.930 
[0.793–0.977]; P<0.001).
Univariate and Multivariate Analyses for Baseline 
Predictors of LV-RR
At univariate analysis, the absence of LGE at baseline was 
strongly associated with LV-RR at follow-up (Table 4). No 
interaction was observed between LGE and other baseline 
variables. Multivariate analysis showed that the absence of 
LGE and decreased LV ejection fraction were the only 2 
predictors of LV-RR at follow-up after correction for other 
baseline covariates, including age, heart rate, New York Heart 
Association class >I, LV end-diastolic volume, and LV and 
RV ejection fractions. This result was also confirmed when 
LV end-systolic volume replaced LV ejection fraction in 
the multivariate model (Table 5). Compared with the model 
containing only the clinical variables, the addition of CMR 
functional parameters to the model enhanced significantly 
the value in predicting LV-RR. Furthermore, when LGE was 
added to the model containing clinical and CMR functional 
parameters, there was a further significant improvement of 
the model in predicting LV-RR (Figure 5). In Bayesian anal-
ysis, the lack of LGE at baseline was the best predictor of 
LV-RR, remaining significant in all selected models in asso-
ciation with one of the other selected variables (Figure I in 
the online-only Data Supplement).
Discussion
The main findings of this study can be summarized as fol-
lows. First, we demonstrated that the absence of LGE at 
baseline CMR was a strong and independent predictor of 
LV-RR in patients with IDCM at 2-year follow-up, irre-
spective of the initial clinical status and the severity of LV 
dilatation and dysfunction. Second, in patients with LGE at 
baseline, there was an increase in LGE extent during follow-
up, and this variation was inversely related to the change in 
LV ejection fraction. Noteworthy, 5 patients (9%) showed 
a marked increase in LGE extent (LGE expansion), which 
was almost always associated with a decrease in LV ejection 
fraction ≥10 U at follow-up.
Table 3. Characteristics of Patients With LGE Expansion











LGE Extent b/FU, 
% of LV
1 64 Female 8 1 108/113 61/77 44/33 5.97/10.66
2 30 Female 6 2 122/136 73/97 40/29 23.92/28.57
3 61 Male 7 3 137/144 87/109 36/24 17.51/23.08
4 55 Female 8 2 89/92 50/51 44/45 17.11/23.08
5 29 Female 11 1 112/136 73/97 40/29 23.92/28.57
b indicates baseline; CM, cardiomyopathy; EDVi, end-diastolic volume index; EF, ejection fraction; ESVi, end-systolic volume 
index; FU, follow-up; LGE, late gadolinium enhancement; LV, left ventricular; Mi, mass index; and RV, right ventricular.
Figure 4. A 64-year-old woman with a 7-month history of idiopathic dilated cardiomyopathy and dyspnea on exertion (New York Heart 
Association class II). Baseline postcontrast basal (A) and midventricular (B) short-axis images showed late gadolinium enhancement 
(LGE) in the midventricular lateral wall (arrows). At follow-up, postcontrast basal (C) and midventricular (D) short-axis images showed an 
increase in LGE extent involving also the basal left ventricular (LV) lateral wall (from 5.97% to 10.66%; Δ value, 4.69% [LGE expansion]). 
End-diastolic (E and G) and end-systolic (F and H) horizontal long-axis images at baseline (E and F; Movie V in the online-only Data Sup-
plement) and follow-up (G and H; Movie VI in the online-only Data Supplement) showed an increase in LV volumes (end-diastolic volume 
from 108 to 113 mL/m2; end-systolic volume from 61 to 77 mL/m2) and reduction in function (ejection fraction from 44% to 33%).
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Reactive (interstitial and perivascular) and reparative 
(replacement) myocardial fibrosis (MF) are 2 hallmarks of 
IDCM.21–23 Contrast-enhanced CMR with LGE is an accu-
rate technique for in vivo detection of replacement MF, and 
previous studies demonstrated that LGE was an independent 
predictor of heart failure–related deaths and hospitalizations 
contributing utmost to outcome in patients with IDCM.24–26 In 
our study, we showed that patients without LGE were more 
likely to respond to OMT than patients with LGE, and LV-RR 
occurred irrespective of the severity of clinical status and the 
degree of LV dilatation and dysfunction at baseline. In fact, at 
initial evaluation, patients with LV-RR were more symptom-
atic and showed higher heart rate and amino-terminal pro-
brain natiuretic peptide levels coupled with larger and more 
dysfunctional LV than patients without LV-RR. Noteworthy, 
the severity of LV dysfunction and the absence of LGE were 
independent predictors of LV-RR, although there was no 
interaction between the 2 variables. We also showed that the 
addition of LGE to the model including clinical and CMR 
functional parameters increased significantly the capacity 
of predicting LV-RR, underscoring the importance of this 
marker in the stratification of patients with IDCM. Our find-
ings are in line with those of 2 recent CMR studies that have 
investigated the capacity of LGE in predicting LV remodeling 
in patients with recent-onset nonischemic cardiomyopathy. In 
a study including 44 patients, Kubanek et al11 demonstrated 
that a lower extent of LGE at baseline CMR was an indepen-
dent predictor of LV-RR at 12 months. However, in this study, 
one third of patients had increased troponin at study entry, 
and endomyocardial biopsy revealed myocardial inflamma-
tion and genomes of cardiotropic viruses in 34% and 66% 
of patients, respectively, indicating an inflammatory or viral 
cause of LV dysfunction in a sizeable number of cases. The 
transient nature of myocardial damage was also suggested by 
the dynamic behavior of LGE observed in the 30 subjects 
who repeated CMR at 12-month follow-up: LGE persisted 
in 13 patients (43%) but disappeared in 7 subjects (23%), 
whereas 2 patients (7%) who were LGE negative at base-
line developed LGE at follow-up. In contrast, in our study, 
patients with suspected myocarditis were excluded. Also, 
all patients with baseline LGE showed LGE at follow-up, 
and no patient without LGE at baseline developed LGE at 
follow-up. In a cohort of 51 patients with new diagnosis of 
nonischemic cardiomyopathy, Leong et al10 reported that the 
extent of LGE was independently associated with the lack 
of improvement in LV ejection fraction at 5-month follow-
up (interquartile range, 4–7 months). Although Leong et al10 
excluded patients with suspected myocarditis, which differed 
from our study, tachycardia-induced cardiomyopathy was 
not considered an exclusion criterion. Importantly, this study 
evaluated the effect of baseline LGE on the variation of LV 
ejection fraction without taking into account the modification 
of LV end-diastolic volume, which is a crucial parameter in 
the assessment of LV remodeling. Our study expands the pre-
vious results by describing the occurrence of LV-RR during a 
2-year follow-up in patients with a longer duration of cardio-
myopathy in whom an acute or subacute transient myocardial 
damage was unlikely.
The identification of patients with LV-RR is of great 
importance for risk stratification and management of patients 
with IDCM. Several trials have shown the benefits of cardiac 
resynchronization therapy and implantable cardioverter-
defibrillator treatment in selected patients with IDCM, but 
at a considerable cost and risk of complications.1–5 Ideally, 
an effective risk stratification should allow early identifica-
tion of high-risk patients likely to respond to OMT, in whom 
device implantation should be at least temporally withheld. 
Current guidelines recommended ≥3 months on OMT before 
proceeding to device implantation.27 Based on our results, 
device treatment can be postponed beyond this time window 
in patients presenting with severe LV dilatation and dys-
function but without LGE because they are likely to recover 
ventricular function on OMT. Conversely, device implanta-
tion should be considered earlier in high-risk patients with 
LGE because they are unlikely to recover ventricular func-
tion on OMT. These findings, whether confirmed by larger 
Table 4. Univariate Analysis for LV-RR at Midterm Follow-Up
Variables at Baseline OR (95% CI) P Value
Age, y 1.051 (1.004–1.101) 0.003
Sex (female) 2.500 (0.809–7.727) 0.111
Heart rate, bpm 1.125 (1.046–1.209) 0.001
Systolic BP, mm Hg 0.979 (0.938–1.022) 0.363
Diastolic BP, mm Hg 0.966 (0.908–1.027) 0.270
Family history of CM, mo 0.663 (0.208–2.114) 0.488
Diabetes mellitus 0.620 (0.110–3.509) 0.589
Hypertension 0.969 (0.330–2.847) 0.955
Smoking 0.855 (0.185–3.950) 0.841
Previous HF hospitalization 3.984 (0.879–18.616) 0.491
Duration of CM, mo 0.940 (0.840–1.051) 0.277
NYHA class >I 8.000 (2.400–26.665) 0.001
NT-proBNP, ng/L 1.003 (0.998–1.007) 0.112
Serum sodium, mEq/L 0.963 (0.729–1.271) 0.789
eGFR, mL/min 0.983 (0.961–1.007) 0.159
Atrial fibrillation 1.647 (0.097–28.094) 0.730
Presence of LBBB 1.733 (0.509–5.902) 0.379
QRS duration, ms 1.015 (0.989–1.042) 0.266
Diastolic dysfunction 1.407 (0.432–5.003) 0.538
Moderate/severe MR 3.694 (0.856–15.944) 0.187
Absence of LGE 11.205 (2.778–45.199) 0.001
LV-EDVi, mL/m2 1.055 (1.024–1.088) 0.001
LV-ESVi, mL/m2 1.065 (1.031–1.099) <0.001
LV-Mi, g/m2 1.028 (1.008–1.057) 0.152
LVEF, % 0.860 (0.799–0.925) <0.001
RV-EDVi, mL/m2 1.009 (0.977–1.041) 0.593
RV-ESVi, mL/m2 1.054 (1.009–1.101) 0.017
RV-EF, % 0.905 (0.849–0.966) 0.003
BP indicates blood pressure; CI, confidence interval; CM, cardiomyopathy; 
EDVi, end-diastolic volume index; EF, ejection fraction; eGFR, estimated 
glomerular filtration rate; ESVi, end-systolic volume index; HF, heart failure; 
LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left 
ventricular; Mi, mass index; MR, mitral regurgitation; NT-pro-BNP, amino-
terminal probrain natiuretic peptide; NYHA, New York Heart Association; OR, 
odds ratio; RR, reverse remodeling; and RV, right ventricular.
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prospective studies, may influence decisively the decision 
making of device implantation.
Furthermore, we observed that in patients with LGE there 
was a significant increase in LGE extent during follow-
up, which was associated with a decrease in LV ejection 
fraction. Notably, 5 patients showed LGE expansion, and 
among these none experienced LV-RR and 4 had a decrease 
in LV ejection fraction ≥10 U during follow-up. Although an 
increase in LGE extent over time has been recently reported 
in hypertrophic cardiomyopathy,28 to the best of our knowl-
edge, this is the first study that indicates that LGE is not fixed 
but is rather a dynamic process in IDCM, and its increase 
is associated with progressive LV dysfunction. Cumulating 
evidence suggests that replacement MF, as detected by LGE 
technique, occurs as a result of progressive myocyte loss via 
necrotic, apoptotic, or autophagic cell pathway and altera-
tion of extracellular matrix constituents,29 which are, in turn, 
influenced by genetic predisposition, myocardial ischemia, 
increased wall stress, and activation of renin–angiotensin–
aldosterone system.29–31 One may speculate that MF is a 
marker of disease severity, reflecting the burden of initial 
damage and ensuing derangements as a result of adverse 
LV remodeling, explaining the poor response to OMT in 
patients with LGE. However, recently Thum et al32 have 
shown that fibroblasts activation in rodents determined pro-
gressive LV dilatation and dysfunction, whereas fibroblast 
inhibition prevented this phenotype, supporting thereby the 
concept that MF might be a primary phenomenon in IDCM 
rather than a stereotyped response to myocardial damage.
Limitations
The study is limited by the small number of enrolled patients. 
In addition, patients were recruited in a tertiary referral cen-
ter, and only patients repeating CMR at 24-month follow-up 
were included in the study, thus leading to a potential selec-
tion bias. However, we think that our study reflects real-life 
practice in which there are no ideal clinical or instrumen-
tal parameters capable of predicting LV-RR. Furthermore, 
we studied patients with a duration of cardiomyopathy <12 
months and in whom neurohormonal therapy was optimized 
after enrollment. Therefore, our results cannot be extrapo-
lated to patients with a longer duration of disease or already 
Figure 5. Multivariate analyses showing the incremental value of late gadolinium enhancement (LGE) in predicting left ventricular 
reverse remodeling compared with models including only clinical parameters or clinical plus cardiovascular magnetic resonance (CMR) 
functional parameters.
Table 5. Multivariate Analysis for Prediction of LV-RR at Midterm Follow-Up
Variables at Baseline
Model 1 Model 2
OR (95% CI) P Value OR (95% CI) P Value
Age, y … … … …
Heart rate, bpm … … … …
NYHA class >I … … … …
Absence of LGE 10.857 (1.844–63.911) 0.008 23.743 (2.887–195.298) 0.003
LV-EDVi, mL/m2 … … … …
LV-ESVI, mL/m2 1.071 (1.026–1.119) 0.002 N/A N/A
LV-EF, % N/A N/A 0.830 (0.748–0.921) <0.001
RV-EF, % … … … …
CI indicates confidence interval; EDVi, end-diastolic volume index; EF, ejection fraction; ESVi, end-systolic volume index; 
HF, heart failure; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricular; Mi, mass index; 
NYHA, New York Heart Association; OR, odds ratio; RR, reverse remodeling; and RV, right ventricular.
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on OMT. The LGE technique allows only the detection and 
quantification of replacement (gross) myocardial MF. The 
quantification of interstitial MF by T1 mapping may be of 
value in this setting.33 The current study included a non-negli-
gible number of patients at an initial phase of IDCM showing 
a mild degree of LV dilatation and systolic dysfunction. Fur-
thermore, only a limited number of patients (n=5) presented a 
New York Heart Association functional class of III/IV at study 
entry. Finally, despite the fact that the stepwise procedure was 
used in the multivariate analysis to determine the independent 
predictors of LV-RR, overfitting could have occurred because 
5 to 10 events should be used per each covariate.34
Conclusions
In patients with IDCM, the absence of LGE is independently 
associated with LV-RR at 2-year follow-up after optimization 
of medical therapy, irrespective of the initial clinical status 
and the severity of LV dilatation and dysfunction. Thus, LGE 
may have key role in the workup and management of IDCM 
with particular regard to decision making of device implan-
tation. The increase in LGE extent over time was associated 
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CLINICAL PERSPECTIVE
We investigated the influence of myocardial fibrosis as detected by cardiovascular magnetic resonance using late gadolinium 
enhancement (LGE) technique on left ventricular (LV) remodeling in 58 consecutive patients with idiopathic dilated car-
diomyopathy diagnosed in the preceding 12 months. Patients underwent cardiovascular magnetic resonance at study enroll-
ment and 24-month follow-up after optimization of medical therapy. LV reverse remodeling was defined as an increase in 
LV ejection fraction ≥10 U, combined with a decrease in LV end-diastolic volume ≥10% at follow-up. We observed that 
the absence of myocardial LGE at baseline cardiovascular magnetic resonance was a strong and independent predictor of 
subsequent LV reverse remodeling at 2 years, irrespective of the initial clinical status and the severity of ventricular dilatation 
and dysfunction. Of note, all patients with baseline LGE demonstrated LGE at follow-up, and no patient without baseline 
LGE developed LGE at follow-up. However, in patients with baseline LGE, there was a substantial increase in LGE extent 
over time, which was inversely related to the variation in LV ejection fraction during follow-up. Five patients (9%) showed 
a marked increase in LGE extent (LGE expansion), and among these none experienced LV reverse remodeling and 4 had a 
decrease in LV ejection fraction ≥10 U at follow-up. On the basis of our results, LGE may become a useful tool when decid-
ing which patients with idiopathic dilated cardiomyopathy should be implanted with a cardioverter-defibrillator or biven-
tricular pacemaker. We also demonstrate that myocardial fibrosis is not a fixed but rather a dynamic process in idiopathic 
dilated cardiomyopathy, and its increase is associated with progressive LV dysfunction.





Figure 1. The Bayesian–model-averaged selected 16 models. The absence of LGE (No-LGE) was 
statistically significant in each model. 
Video Legends 
Video A: Cine balanced-steady state free precession images in horizontal long axis (4-
chamber) view of the patient reported in Figure 2 at baseline.  
Video B: Cine balanced-steady state free precession images in horizontal long axis (4-
chamber) view of the patient reported in Figure 2 at follow-up. 
Video C: Cine balanced-steady state free precession images in horizontal long axis (4-
chamber) view of the patient reported in Figure 3 at baseline.  
Video D: Cine balanced-steady state free precession images in horizontal long axis (4-
chamber) view of the patient reported in Figure 3 at follow-up. 
Video E: Cine balanced-steady state free precession images in horizontal long axis (4-
chamber) view of the patient reported in Figure 4 at baseline.  
Video F: Cine balanced-steady state free precession images in horizontal long axis (4-
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